ArticleBone & joint research2026
Effects of intra-articular injection of dimethyl itaconate combined with systemic vancomycin on periprosthetic joint infection in rats.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aims: This investigation aimed to evaluate the efficacy and safety of intra-articular dimethyl itaconate (DI) combined with systemic vancomycin (Van) for the treatment of periprosthetic joint infections (PJI) induced by Methods: The fifty rats were divided into five groups: Control (Con), PJI, PJI + DI, PJI + Van, and PJI + Van + DI. After three weeks, systemic and local inflammation, osteolysis, bone histomorphometry, bacterial load, and biofilm formation were analyzed. Tartrate-resistant acid phosphatase (TRAP) staining was used to evaluate osteoclast inhibition by DI and vancomycin, and Alizarin Red staining was used to assess its effect on osteogenic differentiation. Results: In vivo, the combination therapy demonstrated superior mitigation of bone loss and intra-articular synovial inflammation compared to Van monotherapy. Furthermore, the co-administration of DI and vancomycin effectively facilitated bacterial and biofilm clearance within the joint, further alleviating the dysregulation between bone resorption and remodelling. Compared to the DI and vancomycin monotherapy group, the Van + DI group showed reduced bacterial counts in implants, bone tissue, and soft-tissue. However, intra-articular DI alone was insufficient for complete eradication of Conclusion: Intra-articular injection of DI combined with systemic vancomycin appears to be a safe and effective therapeutic strategy for PJI in our current rat model.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.